Levofloxacin: update and perspectives on one of the original ‘respiratory quinolones’
- 1 September 2003
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 1 (3) , 371-387
Abstract
The fluoroquinolone class of antimicrobials has enjoyed enormous clinical and marketing success over the past 20 years. These drugs have proven to be extremely useful in a broad range of clinical indications including both common community-acquired as well as nosocomial bacterial infections. Levofloxacin (Levaquin, Tavanic), like ciprofloxacin (Cipro), has established an enviable record of safe and efficacious use, and in many ways has become the agent against which all of the newer fluoroquinolones are judged. New clinical indications in complicated skin and skin structure infections, nosocomial pneumonia and chronic bacterial prostatitis continue to expand the important role of this already versatile drug. In addition, the use of 'short-course, high-dose' therapies are being studied in indications, such as community-acquired pneumonia, in an effort to optimize the efficacy and convenience of the drug while minimizing the future development of resistance. As the use of levofloxacin continues to expand, future challenges will include the threat of increasing antimicrobial resistance and the availability of newer alternative agents, both newer fluoroquinolones as well as agents of other antibiotic classes.Keywords
This publication has 57 references indexed in Scilit:
- High‐Dose, Short‐Course Levofloxacin for Community‐Acquired Pneumonia: A New Treatment ParadigmClinical Infectious Diseases, 2003
- The Battle against Emerging Antibiotic Resistance: Should Fluoroquinolones Be Used to Treat Children?Clinical Infectious Diseases, 2002
- Once‐Daily, High‐Dose Levofloxacin versus Ticarcillin‐Clavulanate Alone or Followed by Amoxicillin‐Clavulanate for Complicated Skin and Skin‐Structure Infections: A Randomized, Open‐Label TrialClinical Infectious Diseases, 2002
- A Critical Review of the FluoroquinolonesDrugs, 2002
- Practice Guidelines for the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2000
- Canadian Guidelines for the Initial Management of Community-Acquired Pneumonia: An Evidence-Based Update by the Canadian Infectious Diseases Society and the Canadian Thoracic SocietyClinical Infectious Diseases, 2000
- The safety profile of the fluoroquinolonesClinical Therapeutics, 2000
- The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosaassessed by combining antibiotic exposure and bacterial susceptibilityJournal of Antimicrobial Chemotherapy, 1999
- Fluoroquinolone Toxicity Profiles: A Review Focusing on Newer AgentsClinical Infectious Diseases, 1999
- The Clinical Pharmacokinetics of LevofloxacinClinical Pharmacokinetics, 1997